Abstract
Background— Measuring C-reactive protein (CRP) has been recommended to identify patients at high risk for coronary heart disease (CHD) with low LDL cholesterol (LDL-C). Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a proinflammatory enzyme associated primarily with LDL. Methods and Results— In a prospective, case cohort study in 12 819 apparently healthy middle-aged men and women in the Atherosclerosis Risk in Communities study, the relation between Lp-PLA 2 , CRP, traditional risk factors, and risk for CHD events over a period of ≈6 years was examined in a proportional hazards model, stratified by LDL-C. Lp-PLA 2 and CRP levels were higher in the 608 cases than the 740 noncases. Both Lp-PLA 2 and CRP were associated with incident CHD after adjustment for age, sex, and race with a hazard ratio of 1.78 for the highest tertile of Lp-PLA 2 and 2.53 for the highest category of CRP versus the lowest categories. Lp-PLA 2 correlated positively with LDL-C ( r =0.36) and negatively with HDL-C ( r =−0.33) but not with CRP ( r =−0.05). In a model adjusted for traditional risk factors including LDL-C, the association of Lp-PLA 2 with CHD was attenuated and not statistically significant. For individuals with LDL-C below the median (130 mg/dL), Lp-PLA 2 and CRP were both significantly and independently associated with CHD in fully adjusted models. For individuals with LDL-C <130 mg/dL, those with both Lp-PLA 2 and CRP levels in the highest tertile were at the greatest risk for a CHD event. Conclusions— Lp-PLA 2 and CRP may be complementary in identifying individuals at high CHD risk who have low LDL-C.
Keywords
Affiliated Institutions
Related Publications
Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT
Background— Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C an...
Prediction of Coronary Heart Disease Using Risk Factor Categories
Background —The objective of this study was to examine the association of Joint National Committee (JNC-V) blood pressure and National Cholesterol Education Program (NCEP) chole...
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
In the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a 19% lower incidence of coronary heart disease (CHD) in cholestyramine-treated men was accompanied b...
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
The recommendations listed in this document are, whenever possible, evidence based. An extensive evidence review was conducted for the period beginning March 2008 through April ...
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the pub...
Publication Info
- Year
- 2004
- Type
- article
- Volume
- 109
- Issue
- 7
- Pages
- 837-842
- Citations
- 613
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1161/01.cir.0000116763.91992.f1